X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $8.0 million Upfront Cash: $8.0 million
Deal Type: Agreement March 27, 2024
Details:
Patients treated with BEOVU (brolucizumab) in KESTREL and KITE demonstrated a significant reduction from baseline in central subfield thickness (CST) starting at week four and continuing up to week 52.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Beovu (brolucizumab, also known as RTH258) 6 mg is approved for the treatment of wet age-related macular degeneration (AMD) in more than 70 countries, including in the US, EU, UK, Japan, Canada and Australia.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
Beovu® (brolucizumab) is approved for the treatment of wet age-related macular degeneration (AMD) currently being developed for diabetic macular edema (DME).
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
KESTREL, KITE and KINGFISHER are global, randomized, double-masked, Phase III, two-year studies comparing the safety and efficacy of Beovu and aflibercept in the treatment of DME.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2021
Details:
The three trials were all testing an experimental once-monthly dosing regimen for Beovu, which is already approved for wet AMD as an injection into the eye every two or three months.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
Beovu met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on select anatomical secondary endpoints at year one versus aflibercept.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2021
Details:
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52).
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
Analyses of US real-world and Phase III data presented at the American Academy of Ophthalmology (AAO) 2020 Meeting reported baseline patient characteristics potentially linked with incidence of inflammation-related adverse events that may occur following treatment with Beovu.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Beovu® is an anti-VEGF treatment that offers patients extended treatment period between doses following initial dose with no compromise in efficacy.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52).
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
CHMP has approved an update to the Beovu® (brolucizumab) Summary of Product Characteristics (SmPC) to include additional information regarding retinal vasculitis and retinal vascular occlusion.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
